The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair

Leukemia

Volumn 23, Issue 12, 2009, Pages 2265-2274

  Maiso, P ^a   Colado, E ^b   Ocio, E M ^a,b   Garayoa, M ^a   Martin J ^b   Atadja, P ^c   Pandiella, A ^a   San Miguel, J F ^a,b  

^a Centro de Investigacion del Cancer   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

acute myeloid leukemia; apoptosis; doxorubicin; HDAC inhibitor; LBH589; panobinostat

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; APOPTOSIS REGULATORY PROTEIN; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; PANOBINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; DNA REPAIR; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; MITOCHONDRION; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; DNA REPAIR; DOXORUBICIN; DRUG SYNERGISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOID, ACUTE; MITOCHONDRIA; TUMOR CELLS, CULTURED;

EID: 74049113783     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.182     Document Type: Article

References (30)

1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368: 1894-1907. (Pubitemid 44794525)
2. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154-1163. (Pubitemid 41130866)
3. Yates JW, Wallace Jr HJ, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 1973; 57: 485-488.
4. Jones LK, Saha V. Chromatin modification, leukaemia and implications for therapy. Br J Haematol 2002; 118: 714-727. (Pubitemid 35007375)
5. Caron C, Boyault C, Khochbin S. Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. Bioessays 2005; 27: 408-415. (Pubitemid 40592597)
6. Sengupta N, Seto E. Regulation of histone deacetylase activities. J Cell Biochem 2004; 93: 57-67.
7. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202. (Pubitemid 33741894)
8. Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci 2001; 58: 728-736. (Pubitemid 32553030)
9. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5: 981-989. (Pubitemid 350080267)
10. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-5552. (Pubitemid 47255934)
11. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060-1066. (Pubitemid 351213383)
12. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005; 45: 495-528. (Pubitemid 40261815)
13. Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006; 66: 5781-5789. (Pubitemid 43927132)
14. Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003; 46: 5097-5116. (Pubitemid 37414179)
15. Colado E, varez-Fernandez S, Maiso P, Martin-Sanchez J, Vidriales MB, Garayoa M et al. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica 2008; 93: 57-66. (Pubitemid 351156152)
16. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
17. Chau BN, Cheng EH, Kerr DA, Hardwick JM. Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1. Mol Cell 2000; 6: 31-40.
18. Kroemer G, Petit P, Zamzami N, Vayssiere JL, Mignotte B. The biochemistry of programmed cell death. FASEB J 1995; 9: 1277-1287.
19. Huang Y, Nakada S, Ishiko T, Utsugisawa T, Datta R, Kharbanda S et al. Role for caspase-mediated cleavage of Rad51 in induction of apoptosis by DNA damage. Mol Cell Biol 1999; 19: 2986-2997. (Pubitemid 29144544)
20. Amin HM, Saeed S, Alkan S. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br J Haematol 2001; 115: 287-297. (Pubitemid 34203490)
21. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005; 11: 77-84. (Pubitemid 40215841)
22. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999; 96: 4592-4597. (Pubitemid 29190381)
23. Suzuki T, Ando T, Tsuchiya K, Fukazawa N, Saito A, Mariko Y et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 1999; 42: 3001-3003. (Pubitemid 29370445)
24. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969-6978. (Pubitemid 34062289)
25. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-36741.
26. Barbetti V, Gozzini A, Rovida E, Morandi A, Spinelli E, Fossati G et al. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene 2008; 27: 1767-1778. (Pubitemid 351380272)
27. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 2003; 278: 12579-12589. (Pubitemid 36800248)
28. Qi H, Ratnam M. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates. Cancer Res 2006; 66: 5875-5882. (Pubitemid 43927142)
29. Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T et al. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 2007; 121: 1138-1148. (Pubitemid 47101654)
30. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205-219. (Pubitemid 38167313)